Breaking News

Tweet TWEET

Study Updates, Financial Strategy, Quarterly Report, Acquisition, and Presentation - Research Report on Vertex, Chimerix, Anika

    Study Updates, Financial Strategy, Quarterly Report, Acquisition, and
   Presentation - Research Report on Vertex, Chimerix, Anika Therapeutics,
                          Charles River, and Repros

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), Chimerix, Inc. (NASDAQ: CMRX),
Anika Therapeutics Inc. (NASDAQ: ANIK), Charles River Laboratories
International, Inc. (NYSE: CRL), and Repros Therapeutics Inc. (NASDAQ: RPRX).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report

On October 17, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
that the TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in
combination with ivacaftor in people with two copies of the F508del mutation
are fully enrolled. Vertex reported that the data from these studies are
expected in mid-2014, and it plans to submit a New Drug Application (NDA) in
the US and a Marketing Authorization Application (MAA) in Europe in H2 2014
for the combination of lumacaftor and ivacaftor. In its presentation made at
the 27th Annual North American Cystic Fibrosis Conference (NACFC), the Company
also reported updates on the multiple ongoing label-expansion studies for
ivacaftor, ongoing and planned Phase 2 combination studies of lumacaftor and
ivacaftor and VX-661 and ivacaftor, and research efforts aimed at beginning
clinical development of a next-generation corrector. The Full Research Report
on Vertex Pharmaceuticals Incorporated - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/e696_VRTX]

--

Chimerix, Inc. Research Report

On October 18, 2013, Chimerix, Inc. (Chimerix) announced the pricing of an
underwritten public offering of 2.48 million shares of its common stock at a
price to the public of $16.50 per share. According to Chimerix, all of the
shares are being sold by certain existing stockholders, who have granted the
underwriters a 30-day option to purchase up to an additional 371,549 shares of
common stock to cover over-allotments, if any. Chimerix reported that it will
not receive any proceeds from the sale of the shares, and the principal
purposes of the offering are to facilitate an orderly distribution of shares
and to increase the Company's public float. The Company further informed that
Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint
book-running managers for the offering. The Full Research Report on Chimerix,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2797_CMRX]

--

Anika Therapeutics Inc. Research Report

On October 15, 2013, Anika Therapeutics Inc. (Anika Therapeutics) announced
that it will release its Q3 2013 results after the market close on Wednesday,
October 30, 2013. The Company reported that it will host its Q3 2013
conference call on Thursday, October 31, 2013 at 9:00 a.m. ET. Anika
Therapeutics stated that interested parties may access the live audio webcast
as well as a replay through the Investor Relations section of the Company
website. The Full Research Report on Anika Therapeutics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ae5d_ANIK]

--

Charles River Laboratories International, Inc. Research Report

On October 7, 2013, Charles River Laboratories International, Inc. (Charles
River) announced that it has successfully completed its acquisition of BRASS
Pte. Ltd. (BRASS). According to Charles River, it aims to accelerate the
growth of its portfolio of products and services in Asia by providing clients
with state-of-the-art microbial detection and identification for manufacturing
in the biopharmaceutical, medical device, and life sciences industries. The
Company reported that BRASS will be renamed as Charles River Endotoxin and
Microbial Detection Singapore Pte. Ltd. (Charles River Singapore), and will
add to Charles River's presence in Asia, which includes sites in Korea, India,
and China. The Full Research Report on Charles River Laboratories
International, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/a37e_CRL]

--

Repros Therapeutics Inc. Research Report

On October 7, 2013, Repros Therapeutics Inc. (Repros) announced that the
Sexual Medicine Society of North America (SMSNA) has accepted key data on
Androxal for presentation at the annual meeting in New Orleans, Louisiana on
November 21 to November 24, 2013. Repros reported that the data presented
belong to the subset analyses of the double-blind, placebo and active control
Phase 2 and 3 studies. Dr. Wayne Hellstrom, Professor of Urology and Chief of
Andrology, Tulane University School of Medicine in New Orleans, said,
"Selection of all three analyses for presentation at the premier sexual health
meeting in the US, shows the increasing interest that the urological community
has in the management of hypogonadism. The data presented not only highlight
the potential utility of Androxal but also the limitations of existing
therapy." The Full Research Report on Repros Therapeutics Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2334_RPRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.